|
Match
|
Document |
Document Title |
|
|
US20090130089 |
ANTI-CD20 ANTIBODIES AND METHODS OF USE
Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies...
|
|
|
US20080292619 |
Pharmaceutical Composition Containing Meltrin Antagonist
Mainly concerning the pharmaceutical field, it is intended to exert an inhibitory effect on the function of meltrin α of promoting the differentiation of adipocytes by preparing a compound serving...
|
|
|
US20080233119 |
COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY LUNG DISEASE
The invention provides a method of modulating a T cell immune response by modulating DR3 function in the T cell, wherein the T cell response causes a symptom of inflammatory lung disease. The...
|
|
|
US20080118510 |
VEGF-RELATED PROTEIN
A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third...
|
|
|
US20080118508 |
Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an...
|
|
|
US20080118495 |
Mammalian Genes Involved in Infection
The present invention relates to nucleic acid sequences and cellular proteins encoded by these sequences that are involved in infection or are otherwise associated with the life cycle of a...
|
|
|
US20080112949 |
Optimized dosing with anti-CD4 antibodies for tolerance induction in primates
The present invention is based, at least in part, on the finding that tolerance can be induced by inhibition of CD4+ cells (and optionally CD8+ cells). Accordingly, the optimized dosing methods of...
|
|
|
US20080107645 |
Neospora caninum isolate
The present invention relates to a novel Neospora caninum isolate from Nowra and extracts thereof. The strain is useful in the development of diagnostic assays for the detection of parasites in...
|
|
|
US20080107644 |
PAI-1 BINDING MODULATORS FOR THE TREATMENT OF OCULAR DISORDERS
The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent...
|
|
|
US20080107643 |
MAMMALIAN CHEMOKINES; RECEPTORS; REAGENTS; USES
Novel chemokines and 7 transmembrane receptors from mammals, reagents related thereto, including purified proteins, specific antibodies, and nucleic acids encoding the chemokines and receptors are...
|
|
|
US20080107642 |
ANTIBODIES AGAINST GPR64 AND USES THEREOF
GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing...
|
|
|
US20080107641 |
METHOD OF TREATING STROKE WITH THROMBOLYTIC AGENT
A method for treating acute ischemic stroke in a human comprises administering tenecteplase to the human in a total dose of about 0.05 to 0.5 mg/kg, given as (a) an initial bolus dose of about...
|
|
|
US20080102066 |
ULTRAPURE TRANSFERRIN FOR PHARMACEUTICAL COMPOSITIONS
The present invention relates to an ultrapure human transferrin, and to methods for manufacturing the ultrapure transferrin. The transferrin may be holo-, apo- or at any desired degree of iron...
|
|
|
US20080102065 |
Erythropoietin receptor extended duration limited agonists
A genus of erythropoietin (Epo) receptor agonists having unique structural, biochemical, and physiological characteristics has been discovered and is referred to herein as Erythropoietin Receptor...
|
|
|
US20080102040 |
INHIBITION OF FACTOR B, THE ALTERNATIVE COMPLEMENT PATHWAY AND METHODS RELATED THERETO
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway...
|
|
|
US20080095778 |
Treatment Of Fungal Infections
A composition comprising an antibody or an antigen binding fragment thereof specific for at least one epitope of hsp90 from an organism of the Aspergillus genus, and at least one antifungal agent...
|
|
|
US20080095774 |
Agents and Methods for Specifically Blocking CD28-Mediated Signaling
The instant invention provides compositions and methods for downmodulation of immune responses, e.g., autoimmune responses. For example, methods of downmodulating an immune response using agents...
|
|
|
US20080095773 |
POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1
The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor...
|
|
|
US20080095772 |
ANTIBODIES AGAINST HUMAN PARATHYROID HORMONE RELATED PROTEIN
Disclosed are an antibody against human para-thyroid-hormone-related protein, a DNA coding for the antibody, a recombinant vector containing the DNA, a transformant transformed with the recombinant...
|
|
|
US20080095765 |
IL-5R-specific antibody composition
The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human interleukin-5 receptor α chain and has complex type N-glycoside-linked...
|
|
|
US20080095764 |
Use of genetically-and epigenetically-altered protocadherins in methods of diagnosing, prognosing, and treating cancer
The present invention provides methods for determining whether a subject has neoplasia, for assessing the efficacy of therapy to treat neoplasia in a subject who has undergone or is undergoing...
|
|
|
US20080095763 |
Cdk9 as Modifier of the Igf Pathway and Methods of Use
Human CDK9 genes are identified as modulators of the IGF pathway, and thus are therapeutic targets for disorders associated with defective IGF function. Methods for identifying modulators of IGF,...
|
|
|
US20080095762 |
GLYCOPROTEIN COMPOSITIONS
The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate...
|
|
|
US20080089931 |
EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
The present invention relates to methods and compositions designed for treatment, management, or prevention of a hyperproliferative cell disease, particular cancer. The methods of the invention...
|
|
|
US20080089923 |
Biodegradable ocular implants and methods for treating ocular conditions
Biodegradable ocular implants are described. The ocular implants include a bioactive agent that can be released within the eye to treat an ocular condition or indication. The implants can be used...
|
|
|
US20080089886 |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human...
|
|
|
US20080089885 |
ANTI-CD20 ANTIBODIES AND METHODS OF USE
Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies...
|
|
|
US20080089884 |
Compositions and methods for the modulation of detrusor activity
The invention relates generally to methods for treating and/or preventing bladder disorders. In certain embodiments the invention comprises methods for the treatment and/or prevention of a bladder...
|
|
|
US20080089882 |
Novel Polypeptide Useful for Cancer Diagnosis and Treatment
The present invention provides a method capable of effectively detecting cancer by finding a novel cancer marker. The present invention also provides a pharmaceutical composition for preventing or...
|
|
|
US20080089849 |
POWDERS FOR INHALATION
The invention therefore relates to protein-containing powders, wherein the proportion of phenylalanine is at least 30% (w/w), or at least 40% (w/w). It has been shown that phenylalanine-containing...
|
|
|
US20080089838 |
Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies
The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers,...
|
|
|
US20080085274 |
Use of certain drugs for treating nerve root injury
The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNT-α comprising an effective amount of a metalloproteinase...
|
|
|
US20080085273 |
VEHICLE FOR THE TRANSPORT OF A CHOSEN MOLECULE TO A CELL
Vehicle for the transport of a chosen molecule to a cell, comprising a SAINT-molecule which is bound to the chosen molecule by means of an electrostatic interaction, in which the SAINT-molecule is...
|
|
|
US20080085261 |
Vaccine Adjuvant
The present invention relates, in general, to a method of enhancing an immune response in a mammal and, in particular, to a method of enhancing an immune response to a vaccine comprising...
|
|
|
US20080075725 |
Novel Immunointeractive Molecules and uses Thereof
The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to...
|
|
|
US20080075719 |
Method for Augmenting B Cell Depletion
The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing...
|
|
|
US20080075716 |
ANTIBODY IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS
The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B...
|
|
|
US20080075715 |
MODIFIED ANTI-CD52 ANTIBODY
The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity.
|
|
|
US20080075714 |
Use of WNT inhibitors to augment therapeutic index of chemotherapy
Methods and compositions are provided for the protection of normal cells from cytoreductive therapy that target proliferating cells, by administering an inhibitor of Wnt signaling pathways. Wnt...
|
|
|
US20080075696 |
Treatment Of Hepatitis C In The Asian Population With Interferon-Beta
The invention relates to the use of IFN-beta in the manufacture of a medicament for the treatment of an HCV infection in a treatment-naïve patient belonging to the Asian population.
|
|
|
US20080075694 |
MVA vaccine
The present invention is directed to a recombinant MVA, which carries a nucleic acid sequence coding for a fusion protein. The present invention is further directed to a kit of parts containing...
|
|
|
US20080075664 |
Control Of Diabetes And Obesity
Provided are methods of increasing resistance to and methods of treating disorders associated with weight gain. Also provided are methods of screening for an agent that prevents or treats a...
|
|
|
US20080069867 |
Diagnostic and/or Remedy for Ovarian Cancer
It was found that an antibody containing the amino acid sequences described in the sequence listing as SEQ ID NOS: 1 to 6 was an antibody having reactivity also to ovarian cancer, as well as the...
|
|
|
US20080069815 |
ANTI-OSTEOPONTIN ANTIBODY AND USE THEREOF
An anti-osteopontin antibody which inhibits the binding of an integrin recognizing RGD sequence to osteopontin or its fragment, and which inhibits the binding of an integrin recognizing SVVYGLR...
|
|
|
US20080069813 |
ISOLATED BOVINE IgG HEAVY CHAIN PROTEIN AND ITS USE AS AN ANTIMICROBIAL
A new protein derived from acid hydrolyzed IgG concentrate which has a molecular weight of about 55,000, and is activated by heat within the defined narrow temperature range provides resulting...
|
|
|
US20080069812 |
IAP bir domain binding compounds
Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II
or a salt thereof, in which R 1 , R 2 , R 3 , R 100 , R 200 , R 300 , A, A 1 , BG,...
|
|
|
US20080069811 |
Fsh and Fsh Receptor Modulator Compositions and Methods for Inhibiting Osteclastic Bone Resorption and Bone Loss in Osteoporosis
The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders.
|
|
|
US20080069795 |
Amelioration of Drug-Induced Toxicity
Kidney toxicity which is induced by cisplatin and other therapeutic and diagnostic agents, limits the effectiveness of the therapy or diagnosis. Modulation or depletion of T cells ameliorates the...
|
|
|
US20080069772 |
Treatment of transformed or infected biological cells
The present invention relates to a therapeutic or/and diagnostic substance. Furthermore it relates to an expression vector, to a composition comprising the afore-mentioned substance or/and the...
|
|
|
US20080063650 |
mCRP antagonists and their uses
A therapeutic composition for treating a proliferative disorder includes a membrane-bound complement regulatory protein (mCRP) antagonist, a therapeutic ligand that is capable of activating...
|